尽管作物科学业务有所下滑,2017年第二季度拜耳集团的业绩与去年持平。CEO沃纳·保曼(Werner Baumann)在近日发布的第二季度中期报告中表示:“作物科学业务在世界第二大农业市场巴西受到渠道高库存的影响,在该业务领域我们的销售额和盈利显著下滑。但是,我们在处方药业务和动物保健业务的盈利和利润取得了鼓舞人心的增长。”健康消费品业务有所下滑,主要归因于美国市场环境困难。公司生命科学业务的销售额和盈利 Despite the decline in the crop science business, the performance of the Bayer Group in the second quarter of 2017 was unchanged from the previous year. In a recently released second quarter interim report, Werner Baumann, CEO, said: “The CropScience business is affected by the high channel inventory in Brazil, the world’s second largest agricultural market, where our sales And earnings, but we have seen encouraging growth in the profitability and profitability of the prescription drug business and the animal health business. ”The decline in the health consumer products business was mainly attributable to the difficult market environment in the United States. Sales and earnings of the company’s life sciences business